CLAIMS

1. A combination comprising:
    i) a first component selected from the group consisting of:
        a) a polypeptide comprising the sequence SEQ ID NO: 1 or a functionally equivalent variant thereof;
        b) a conjugate comprising a polypeptide comprising the sequence SEQ ID NO: 1 or a functionally equivalent variant thereof and a chemical moiety that facilitates cellular uptake of the polypeptide or of the functionally equivalent variant thereof;
        c) a polynucleotide encoding the polypeptide of a) or the conjugate of b);
        d) a vector comprising the polynucleotide according to c); and
        e) a cell capable of secreting into the medium the polypeptide according to a) or the conjugate according to b);
    and
    ii) a second component that is a BRAF inhibitor.

2. The combination according to claim 1, wherein the first component is a polypeptide comprising the sequence SEQ ID NO: 1.

3. The combination according to claim 1, wherein the functionally equivalent variant of SEQ ID NO: 1 is selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO; 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

4. The combination according to any one of claims 1 or 3, wherein the chemical moiety that facilitates the cellular uptake of the polypeptide or of the functionally equivalent variant thereof is a cell-penetrating peptide sequence and wherein said cell penetrating peptide sequence and said polypeptide or functionally equivalent variant thereof form a fusion protein.

5. The combination according to any one of claims 1 or 3 to 4, wherein the conjugate additionally comprises a further nuclear localization signal.

6. The combination according to any one of claims 1 to 5, wherein the BRAF inhibitor is selected from the group consisting of dabrafenib, vemurafenib and encorafenib.

7. The combination according to claim 6, wherein the BRAF inhibitor is dabrafenib.

8. A pharmaceutical composition comprising a pharmaceutically effective amount of a combination according to any one of claims 1 to 7 and a pharmaceutically acceptable excipient.

9. A combination according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8 for use in medicine.

10. Use of a combination according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8 in the manufacture of a medicament for prevention and/or treatment of cancer.

11. The use according to claim 10, wherein the cancer is selected from the group consisting of melanoma, colorectal cancer and breast cancer.

12. The use according to claim 11, wherein the cancer is melanoma.

13. The use according to any one of claims 10 to 12, wherein the cancer is a cancer having a BRAF mutation.

14. The use according to any one of claims 10 to 13, wherein the cancer is a cancer resistant to BRAF inhibitors.

15. The use according to any one of claims 9 to 14, wherein the first component is suitable for intravenous administration and the second component is suitable for oral administration.